AML is characterized by distinct cell populations; those cells with the potential for leukemia initiation were termed leukemia stem cells (LSCs), considered pivotal in the re-emergence of AML during relapse, endowed with an increased capacity for activation of NFκB, and associated with poorer clinical outcomes [76,77,78,79]. This evidence concerns the gene NFKB1 and acute myeloid leukemia.